Latest News - Biogen
Top Corporates Hub
Biogen
Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation
13.08.2026 13:52
Investing.com -- Wolfe Research upgraded two major pharmaceutical companies to Outperform on Thursday, citing stronger growth prospects, attractive valuations and a series of upcoming clinical catalysts.
Biogen (BIIB) Q2 2026 Earnings Call Transcript
08.08.2026 00:02
Growth portfolio revenue surpassed legacy MS franchise for second consecutive quarter.
BIIB Q2 Deep Dive: Portfolio Expansion and Pipeline Readouts Drive Upbeat Outlook
01.08.2026 15:47
Biotech company Biogen (NASDAQ:BIIB) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 3.4% year on year to $2.74 billion. Its non-GAAP profit of $3.60 per share was 75.8% above analysts’ consensus estimates.
Biogen Q2 Earnings Call Highlights
29.07.2026 14:04
Biogen (NASDAQ:BIIB) reported second-quarter 2026 total revenue of $2.7 billion, up 3% from a year earlier, as growth products and the recently completed acquisition of Apellis contributed to results. Core pharmaceutical revenue rose 4% year over year to $1.8 billion, while the company’s growth port
Biogen (BIIB) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
29.07.2026 14:00
Although the revenue and EPS for Biogen (BIIB) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Biogen Beats Second-Quarter Expectations as Growth Portfolio Drives Revenue Higher
29.07.2026 12:16
Biogen (NASDAQ:BIIB) reported stronger-than-expected second-quarter results on Wednesday, with revenue and adjusted earnings exceeding Wall Street forecasts as its expanding portfolio of growth products continued to offset weakness in its legacy multiple sclerosis business. The biotechnology company posted revenue of $2.
Biogen (NASDAQ:BIIB) Reports Upbeat Q2 CY2026
29.07.2026 12:15
Biotech company Biogen (NASDAQ:BIIB) announced better-than-expected revenue in Q2 CY2026, with sales up 3.4% year on year to $2.74 billion. Its non-GAAP profit of $3.60 per share was 75.8% above analysts’ consensus estimates.
Why This Drugmaker’s Earnings Guidance Cut Doesn’t Tell the Full Story
29.07.2026 12:02
Biogen’s growth portfolio, which includes one closely watched Alzheimer’s drug, is a bright spot in the second quarter.
Biogen Inc. (BIIB) Q2 Earnings and Revenues Top Estimates
29.07.2026 11:30
Biogen (BIIB) delivered earnings and revenue surprises of +18.42% and +9.40%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Biogen: The Turnaround Is Real Enough To Buy (Rating Upgrade)
29.07.2026 11:29
Biogen Inc. upgraded to Buy: Q2 revenue +3%, LEQEMBI traction, and felzartamab catalysts drive upside. Click for this BIIB earnings update.
Earnings roundup: Biogen’s ‘resiliency,’ AstraZeneca’s growth pitch and GSK’s oncology push
29.07.2026 11:13
Better-than-expected sales helped Biogen regain the support of investors, while AstraZeneca and GSK worked to convince Wall Street that they can hit ambitious revenue targets.
Biogen Q2 revenue, adjusted EPS beat estimates as growth portfolio lifts sales
29.07.2026 10:45
Investing.com -- Biogen reported second-quarter revenue and adjusted profit above analysts’ estimates on Wednesday, helped by 24% growth in its Growth Portfolio and stronger revenue from recently acquired products, although sales of its Alzheimer’s drug Leqembi narrowly missed expectations.
Sales of Leqembi® totaled 29.3 billion yen in the second quarter 2026
29.07.2026 10:30
BioArctic AB's (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi for the second quarter 2026, in conjunction with their partner Biogen's second quarter report. In total, sales of JPY 29.3 billion were recorded in the period. This results in a royalty to BioArctic amounting to SEK 179 million, which is an increase of approximately 10 percent compared to the royalty recorded by BioArctic for the second quarter 2025.
Biogen Raises Revenue Guidance as Growth Portfolio Outpaces Legacy Blockbuster Drugs
29.07.2026 10:29
Biogen’s growth portfolio, which includes one closely watched Alzheimer’s drug, is a bright spot in the second quarter.
Biogen Inc. 2026 Q2 - Results - Earnings Call Presentation
29.07.2026 09:01
2026-07-29. The following slide deck was published by Biogen Inc.
Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?
27.07.2026 16:36
Harmony Biosciences, Acadia, Biogen, Insmed and Agios show positive Earnings ESPs ahead of Q2 results, setting up closely watched earnings reports.
Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for
22.07.2026 14:00
Biogen (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Profitable Stocks We Steer Clear Of
21.07.2026 12:46
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.
VERAXA Biotech Shows Regulatory Progress on Cancer Therapy Platform
20.07.2026 16:15
By Daniella Parra VERAXA Biotech said it received positive scientific advice from Germany’s Paul-Ehrlich-Institute supporting a preclinical development plan for its experimental BiTAC-TCE cancer therapy platform. The feedback provides greater regulatory clarity and reduces some early-stage development risk as the company advances its lead candidate toward clinical trials, it said. READ MORE The Cancer […] The post VERAXA Biotech Shows Regulatory Progress on Cancer Therapy Platform appeared first
Stoke Therapeutics: Its Dravet Syndrome Lead Asset Enters The Last Stretch
19.07.2026 02:15
Stoke Therapeutics outlook: Phase 3 Dravet program catalysts, strong cash runway, and upside from partnerships. Click for more on STOK stock.